Pier Paolo Olimpieri

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Venues

Università degli Studi di Roma La Sapienza

Università degli Studi di Roma La Sapienza (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Roma La Sapienza Jan 13 2014 - Sep 30 2017

Italy

PostDoc :: Physics department

Education History

Università degli Studi di Roma La Sapienza Sep 01 2011 - Jan 12 2014

Italy

PHD :: Molecular medicine

Sapienza University of Rome Oct 01 2003 - Jul 22 2009

Italy

MSC :: Pharmaceutical chemistry

Publications

Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò, Lucia Tognolo, Maria Pia Ballardini, Antonio Urso, Mariarosaria Sessa, Silvia Gambara, Francesca Cura, Monica Fortini, Paolo Ghia, Antonio Cuneo, Pierluigi Russo
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency. Blood cancer journal 13 (1) (2023)
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò, Lucia Tognolo, Maria Pia Ballardini, Antonio Urso, Mariarosaria Sessa, Silvia Gambara, Francesca Cura, Monica Fortini, Paolo Ghia, Antonio Cuneo, Pierluigi Russo
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency. Blood cancer journal 13 (1) (2023)
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Luca Tomassini, Laura D'Erasmo, Maurizio Rocco Averna, Alberto Zambon, Alberico Luigi Catapano, Pierluigi Russo
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. Journal of the American Heart Association (2023)
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò, Lucia Tognolo, Maria Pia Ballardini, Antonio Urso, Mariarosaria Sessa, Silvia Gambara, Francesca Cura, Monica Fortini, Paolo Ghia, Antonio Cuneo, Pierluigi Russo
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency. Blood cancer journal 13 (1) (2023)
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò, Lucia Tognolo, Maria Pia Ballardini, Antonio Urso, Mariarosaria Sessa, Silvia Gambara, Francesca Cura, Monica Fortini, Paolo Ghia, Antonio Cuneo, Pierluigi Russo
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency. Blood cancer journal 13 (1) (2023)
Pierluigi Russo, Evelina Tacconelli, Pier Paolo Olimpieri, Simone Celant, Antonietta Colatrella, Luca Tomassini, Giorgio Palù
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses 14 (6) (2022)
Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, Odoardo Olimpieri, Fabrizio Pane, Alessandra Iurlo, Valentina Summa, Paolo Corradini, Pierluigi Russo
Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA). British journal of haematology 198 (6) (2022)
Francesco Ambrosetti, Tobias Hegelund Olsen, Pier Paolo Olimpieri, Brian Jiménez-García, Edoardo Milanetti, Paolo Marcatilli, Alexandre M J J Bonvin
proABC-2: PRediction of AntiBody contacts v2 and its application to information-driven docking. Bioinformatics (Oxford, England) 36 (20) (2021)
Giovanni Palladini, Simone Celant, Paolo Milani, Valentina Summa, Giovanni Affronti, Pier Paolo Olimpieri, Sandra Petraglia, Andrea Foli, Mario Nuvolone, Giampaolo Merlini, Pierluigi Russo
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. Leukemia & lymphoma (2021)
Massimo Breccia, Pier Paolo Olimpieri, Odoardo Olimpieri, Fabrizio Pane, Alessandra Iurlo, Paolo Foggi, Alessia Cirilli, Antonietta Colatrella, Marcello Cuomo, Lucia Gozzo, Valentina Summa, Paolo Corradini, Pierluigi Russo, null null
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer medicine 9 (12) (2020)

Pier Paolo Olimpieri.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pier Paolo Olimpieri